Rich Pharmaceuticals Inc (RCHA)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Rich Pharmaceuticals Inc (RCHA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013533
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:44
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Rich Pharmaceuticals Inc (Rich Pharmaceuticals) is a biopharmaceutical company that offers discovery and development of therapies for the treatment of cancer and neurological disorders. The company’s pipeline portfolio offers a lead drug candidate for the treatment of acute myeloid leukemia (AML). It also develops compounds acure myeloid lekemia and hodgkins lymphoma through phase clinical trials. Rich Pharmaceuticals compounds are also used for the treatment of Hodgkin’s lymphoma. The company offers administration of TPA and toxicity associated with TPA, predominately dyspnea, fever, chills, venous irritation and hematuria. It works in collaboration with non-profit institutes to develop technologies. Rich Pharmaceuticals is headquartered in Beverly Hills, California, the US.

Rich Pharmaceuticals Inc (RCHA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Rich Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Rich Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Rich Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Rich Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Rich Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Rich Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Rich Pharma Acquires Patents for Treatment of Hodgkin’s Lymphoma from Richard l. Chang and Imagic 12
Rich Pharma to Acquire Certain Assets from Imagic 13
Partnerships 14
Rich Pharma Enters into Agreement with Mega Bridge 14
Rich Pharma Partners with Theradex Systems 15
Rich Pharma Partners with CMIC Asia-Pacific 16
Rich Pharma Extends Agreement with Theradex Systems 17
Equity Offering 18
Rich Pharma to Raise up to USD2 Million in Private Placement of Shares 18
Rich Pharma to Raise USD4.5 Million in Private Placement of Common Stock 19
Rich Pharma Completes Public Offering Of Shares For US$0.4 Million 20
Rich Pharma Raises USD0.3 Million in Private Placement of Units 21
Rich Pharma Raises Funds in Private Placement of Units 22
Debt Offering 23
Rich Pharma Raises Funds through Private Placement of 8% Notes Due 2016 23
Rich Pharma Raises Funds through Private Placement of 8% Notes Due 2016 24
Rich Pharma Raises USD0.1 Million in Private Placement of 8% Notes Due 2016 25
Rich Pharma Raises Funds in Private Placement of 8% Notes 26
Rich Pharma Raises Funds in Private Placement of 8% Notes Due 2015 27
Rich Pharma Raises Funds in Private Placement of 8% Notes Due 2015 28
Rich Pharma Raises Funds in Private Placement of 8% Notes Due 2015 29
Rich Pharma Raises Funds in Private Placement of 8% Notes Due 2015 30
Rich Pharma Raises Funds in Private Placement of 8% Notes Due 2015 31
Rich Pharma Raises Funds in Private Placement of Notes Due 2015 32
Rich Pharma Raises USD0.5 Million in Private Placement of Notes 33
Rich Pharma Raises USD0.4 Million in Private Placement of Notes 34
Rich Pharmaceuticals Inc – Key Competitors 35
Rich Pharmaceuticals Inc – Key Employees 36
Rich Pharmaceuticals Inc – Locations And Subsidiaries 37
Head Office 37
Recent Developments 38
Strategy And Business Planning 38
Feb 16, 2016: Rich Pharmaceuticals Highlights Goals and Objectives for 2016 38
Financial Announcements 39
Apr 06, 2017: Rich Pharmaceuticals announces Industry Veteran to Join CannCodex 39
Corporate Communications 40
Apr 10, 2017: Rich Pharmaceuticals Welcomes New Board Member 40
Legal and Regulatory 41
Jun 08, 2017: Rich Pharmaceuticals Announces Institutional Review Board Submission 41
Other Significant Developments 42
May 31, 2017: Rich Pharmaceuticals Announces Clinical Site in Thailand 42
Sep 27, 2016: Rich Pharmaceuticals Announces Quarterly Milestones 43
Appendix 44
Methodology 44
About GlobalData 44
Contact Us 44
Disclaimer 44

List of Tables
Rich Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Rich Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Rich Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Rich Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Rich Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Rich Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Rich Pharma Acquires Patents for Treatment of Hodgkin's Lymphoma from Richard l. Chang and Imagic 12
Rich Pharma to Acquire Certain Assets from Imagic 13
Rich Pharma Enters into Agreement with Mega Bridge 14
Rich Pharma Partners with Theradex Systems 15
Rich Pharma Partners with CMIC Asia-Pacific 16
Rich Pharma Extends Agreement with Theradex Systems 17
Rich Pharma to Raise up to USD2 Million in Private Placement of Shares 18
Rich Pharma to Raise USD4.5 Million in Private Placement of Common Stock 19
Rich Pharma Completes Public Offering Of Shares For US$0.4 Million 20
Rich Pharma Raises USD0.3 Million in Private Placement of Units 21
Rich Pharma Raises Funds in Private Placement of Units 22
Rich Pharma Raises Funds through Private Placement of 8% Notes Due 2016 23
Rich Pharma Raises Funds through Private Placement of 8% Notes Due 2016 24
Rich Pharma Raises USD0.1 Million in Private Placement of 8% Notes Due 2016 25
Rich Pharma Raises Funds in Private Placement of 8% Notes 26
Rich Pharma Raises Funds in Private Placement of 8% Notes Due 2015 27
Rich Pharma Raises Funds in Private Placement of 8% Notes Due 2015 28
Rich Pharma Raises Funds in Private Placement of 8% Notes Due 2015 29
Rich Pharma Raises Funds in Private Placement of 8% Notes Due 2015 30
Rich Pharma Raises Funds in Private Placement of 8% Notes Due 2015 31
Rich Pharma Raises Funds in Private Placement of Notes Due 2015 32
Rich Pharma Raises USD0.5 Million in Private Placement of Notes 33
Rich Pharma Raises USD0.4 Million in Private Placement of Notes 34
Rich Pharmaceuticals Inc, Key Competitors 35
Rich Pharmaceuticals Inc, Key Employees 36

★海外企業調査レポート[Rich Pharmaceuticals Inc (RCHA)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • HollyFrontier Corp (HFC):石油・ガス:M&Aディール及び事業提携情報
    Summary HollyFrontier Corp (HollyFrontier) is an independent energy company. It carries out crude oil refining and wholesale marketing of refined petroleum products. The company produces and markets high-value light products such as gasoline, diesel, jet fuel, specialty lubricant products, heavy pro …
  • Samsung Engineering Co Ltd (028050):企業の財務・戦略的SWOT分析
    Samsung Engineering Co Ltd (028050) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Dong-A Socio Holdings Co Ltd (000640):製薬・医療:M&Aディール及び事業提携情報
    Summary Dong-A Socio Holdings Co Ltd (Dong-A Socio Holdings), formerly Dong-A Pharmaceutical Co., Ltd., offers business management services. It is a subsidiary of Dong-A Socio Group. It operates in various markets such as pharmaceuticals, food and beverages, logistics, IT, and materials. The group f …
  • Louisville Gas and Electric Co:電力:M&Aディール及び事業提携情報
    Summary Louisville Gas and Electric Company (LG&E) a subsidiary of LG&E and KU Energy LLC is an electric and natural gas utility. The utility offers gas storage and distribution services to residential and business customers. It has a total regulated generation capacity of three thousand megawatts. …
  • Innova Biosciences Ltd:医療機器:M&Aディール及び事業提携情報
    Summary Innova Biosciences Ltd (Innova), a subsidiary of Sygnis AG is a provider of bioconjugation technologies and services. The company products include antibody labeling kits, antibody purification kits, affinity resins, gold nanoparticle kits, immunogen kits, rapid Ab labeling kits and others. I …
  • QGEP Participacoes SA (QGEP3):企業の財務・戦略的SWOT分析
    Summary QGEP Participacoes SA (QGEP), a subsidiary of Queiroz Galvao Group, is an oil and gas company that explores, develops and produces oil and gas properties. The company's exploration properties include Santos Basin, Espirito Santo Basin, Camamu-Almada Basin, Sergipe-Alagoas Basin, Pernambuco-P …
  • Baker & McKenzie LLP:企業の戦略的SWOT分析
    Baker & McKenzie LLP - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Euroclear Plc:企業の戦略・SWOT・財務分析
    Euroclear Plc - Strategy, SWOT and Corporate Finance Report Summary Euroclear Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • The Real Good Food Company plc:戦略・SWOT・企業財務分析
    The Real Good Food Company plc - Strategy, SWOT and Corporate Finance Report Summary The Real Good Food Company plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Tesco Plc (TSCO):企業の財務・戦略的SWOT分析
    Tesco Plc (TSCO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Viking Therapeutics Inc (VKTX):企業の財務・戦略的SWOT分析
    Summary Viking Therapeutics Inc (Viking Therapeutics) is a clinical-stage biopharmaceutical company that develops novel therapies for patients suffering from metabolic and endocrine disorders. The company’s lead clinical program product candidate include VK5211, an orally available, non-steroidal se …
  • Prism Medical Ltd:医療機器:M&Aディール及び事業提携情報
    Summary Prism Medical Ltd (Prism Medical), a subsidiary of Handicare AB is a medical device company that manufacturer and provides durable medical equipment. The company offers products such as fixed ceiling lifts, portable ceiling lifts, portable track systems, mobile floor lifts, sling systems, ho …
  • Xylem Inc (XYL):企業の財務・戦略的SWOT分析
    Xylem Inc (XYL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Commerce Resources Corp (CCE):企業の財務・戦略的SWOT分析
    Summary Commerce Resources Corp (Commerce Resources) is a minerals exploration and development company that explores for deposits of rare earth elements and rare metals. The company acquires, explores, produces, develops, evaluates mineral resource properties, and others. It explores for niobium and …
  • PureCircle Ltd:企業の戦略・SWOT・財務情報
    PureCircle Ltd - Strategy, SWOT and Corporate Finance Report Summary PureCircle Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • CapitaLand Limited:企業のM&A・事業提携・投資動向
    CapitaLand Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's CapitaLand Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), d …
  • BirchBioMed Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary BirchBioMed Inc (BirchBioMed) is a biomedical company that concentrate on the development, clinical evaluation and commercialization of anti-scarring drugs, autoimmune therapeutics and novel strategies for transplantation. The company’s proprietary and patented lead drug candidate, FS2 is be …
  • IRPC Public Company Limited:企業の戦略・SWOT・財務情報
    IRPC Public Company Limited - Strategy, SWOT and Corporate Finance Report Summary IRPC Public Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Impellam Group plc (IPEL):企業の財務・戦略的SWOT分析
    Impellam Group plc (IPEL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Garanti Technology:企業の戦略・SWOT・財務情報
    Garanti Technology - Strategy, SWOT and Corporate Finance Report Summary Garanti Technology - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆